Assessing Sacubitril/Valsartan’s Impact on Right Heart Failure: A Comprehensive Study

Background and Objective: Right heart failure (RHF) represents a complex clinical challenge, often resulting from pulmonary hypertension, left heart dysfunction or congenital heart diseases. Unlike left heart failure, treatments and interventions specifically targeting RHF are less defined, contributing to poorer patient outcomes and quality of life. Sacubitril/Valsartan, a novel therapy originally approved for treating left heart failure, has shown potential due to its dual action of inhibiting neprilysin and blocking angiotensin receptors. Given its success in improving left ventricular function, there is increasing interest in exploring its efficacy and mechanisms in managing right heart failure. This study aims to fill the gap in current knowledge by systematically assessing the impact of Sacubitril/Valsartan on right heart function, utilizing comprehensive diagnostic tools and functional assessments to delineate its potential benefits and implications for therapy in right heart failure. Materials and Methods: A randomized, controlled trial was conducted involving patients diagnosed with right heart failure. Participants were divided into two groups: The treatment group received Sacubitril/Valsartan, while the control group received standard care. Baseline and post-treatment assessments included echocardiographic evaluation of right ventricular function, electrocardiographic analysis and the 6-Minute Walk Test (6MWT) to measure functional capacity. Statistical analysis was performed to compare the changes within and between groups. Results: The treatment group showed significant improvements post-treatment in echocardiographic parameters (RV ejection fraction (%), TAPSE, RA size), electrocardiographic findings (narrowing of QRS duration, shortening of QT interval and reduced heart rate) and functional capacity as measured by the 6MWT. These changes were statistically significant compared to the control group, indicating enhanced right ventricular function, improved cardiac electrical stability and increased exercise capacity. Sacubitril/Valsartan demonstrated significant benefits in patients with right heart failure, improving right ventricular function, cardiac electrical activity and functional capacity. Conclusion: These findings suggest Sacubitril/Valsartan as a viable therapeutic option for enhancing the clinical outcomes of patients with right heart failure. Further research is encouraged to explore the long-term benefits and potential integration into standard care protocols.